Breast Reconstruction Following Mastectomy or Lumpectomy - (0178) — MM 0178 | CIGNA Coverage Update

Cigna modified MM 0178, its breast reconstruction coverage policy following mastectomy or lumpectomy, effective September 26, 2025. Here's what your billing team needs to know.

Cigna Healthcare updated Coverage Policy MM 0178 covering breast reconstruction after mastectomy or lumpectomy. This policy governs 35 CPT codes and 30 HCPCS codes — from tissue expander placement (CPT 19357) and free flap reconstruction (CPT 19364) to external breast prostheses (L8020, L8030) and mastectomy bras (L8000–L8002). If your practice bills reconstructive breast surgery or durable prosthetics for post-mastectomy patients, this update deserves a close look before the September 26, 2025 effective date.

Quick-Reference Table

Cigna Breast Reconstruction Coverage Criteria and Medical Necessity Requirements 2025

The Cigna breast reconstruction coverage policy under MM 0178 in the Cigna system draws a sharp line between what qualifies as medically necessary and what gets flagged as experimental. The majority of standard reconstructive procedures qualify as covered — but only when your documentation supports the specific criteria the policy requires.

The core covered procedures include immediate implant placement on the day of mastectomy (CPT 19340), delayed insertion or replacement (CPT 19342), tissue expander placement (CPT 19357), and autologous flap techniques including the latissimus dorsi flap (CPT 19361), free flap reconstruction such as DIEP and SIEA (CPT 19364), single-pedicled TRAM (CPT 19367 and 19368), and bipedicled TRAM (CPT 19369). Nipple and areola tattooing (CPT 11920 and 11921) also meets medical necessity criteria when the applicable documentation requirements are satisfied.

The policy also covers prosthetic-side needs. External breast prostheses — including silicone forms (L8030, L8031), mastectomy bras with or without integrated forms (L8000, L8001, L8002), custom prostheses (L8035), and nipple prostheses (L8032, L8033) — are covered when medical necessity is established. For DME suppliers billing these HCPCS codes, your documentation needs to clearly connect the item to a qualifying mastectomy or lumpectomy.

Prior authorization requirements for specific reconstructive procedures under this policy are something you need to confirm directly with Cigna before scheduling. This policy governs coverage position — prior auth rules sit in Cigna's authorization lookup tool, not here. Don't assume a covered procedure skips prior auth.

Biologic implants for soft tissue reinforcement (CPT 15777) are covered when criteria are met, as is acellular dermal matrix reported with Q4116 (Alloderm), Q4122 (Dermacell), and Q4128 (Flex HD or Allomax HD matrix). AlloMax™ specifically is reportable using C1781 (implantable mesh) or Q4100 (skin substitute, NOS). Cortiva™ is reportable using C9399 (unclassified drugs or biologicals). If your team bills these materials, make sure you're using the correct HCPCS code for the specific product — a mismatch here is a clean path to claim denial.

Revision procedures also land on the covered list. CPT 19370 (peri-implant capsule revision, including capsulotomy), CPT 19371 (complete peri-implant capsulectomy), and CPT 19380 (revision of reconstructed breast) are covered when the applicable criteria are met. Custom implant preparation (CPT 19396) is covered as well.

Cigna Breast Reconstruction Exclusions and Non-Covered Indications

Several procedure categories are flat-out off the covered list under MM 0178. Subcutaneous filler injections — CPT 11950 (1 cc or less), 11951 (1.1 to 5.0 cc), 11952 (5.1 to 10.0 cc), and 11954 (over 10.0 cc) — are all classified as experimental, investigational, or unproven when used in breast reconstruction. The same applies to CPT 19366 (breast reconstruction with other technique) and CPT 19499 (unlisted breast procedure).

On the HCPCS side, several acellular dermal and collagen matrix products are also experimental. C9354 (Veritas pericardial matrix), C9358 and C9360 (SurgiMend collagen matrix in fetal and neonatal bovine forms), C9364 (Permacol porcine implant), Q4130 (Strattice), and Q2026 (Radiesse injection) are all non-covered. C1763 (nonhuman connective tissue) and J3590 (unclassified biologics) are experimental when used in this context.

S-codes for reconstructive flaps — S2066 (GAP flap), S2067 (stacked DIEP flap), and S2068 (DIEP or SIEA flap) — are experimental or investigational for the diseased or affected breast. This is an important distinction. DIEP and SIEA reconstruction is covered when billed with CPT 19364, but billing the same surgery with S2068 puts you in non-covered territory. This matters for your charge capture setup.

The implantable prosthesis codes C1789 and L8600 also land in experimental or non-covered status in certain contexts. The policy's group label references "diseased/affected breast" — which suggests these codes are non-covered for the reconstructed breast itself, separate from a contralateral augmentation scenario. If your team bills implantable prostheses under these HCPCS codes, confirm the clinical scenario lines up with what Cigna allows.

CPT 15839 (excision of excessive skin, other area) and CPT 15877 (suction-assisted lipectomy, trunk) are considered incidental to flap breast reconstruction. Don't bill them separately — they'll be bundled, and the claim will be reduced or denied.

CPT 15860 (IV injection for vascular flow testing in flap or graft) is considered integral to the primary procedure. Same rule applies — bill it separately and you're inviting a denial.

Coverage Indications at a Glance

Cigna Breast Reconstruction Billing Guidelines and Action Items 2025

CPT, HCPCS, and ICD-10 Codes for Breast Reconstruction Under MM 0178

Covered CPT Codes (When Medical Necessity Criteria Are Met)

Covered HCPCS Codes (When Medical Necessity Criteria Are Met)

Incidental / Integral Codes — Do Not Bill Separately

Experimental / Investigational / Non-Covered Codes